Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

NCT ID: NCT03936426

Last Updated: 2020-04-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-09
• Study Completion Date: 2019-09-19

Brief Summary

The primary purpose of this study is to investigate the safety and tolerability of a single dose of Cu-64 SARTATE and multiple doses of Cu-67 SARTATE administered to participants with meningioma. All participants in this study will be injected with a single dose of Cu-64 SARTATE to demonstrate how it is absorbed in the body. Then participants will receive individualised doses of Cu-67 SARTATE for up to 4 cycles.

Detailed Description

This is a single centre, open label, non-randomised, single cohort, multiple dose study of Cu-67 SARTATE administered to male and female participants diagnosed with grade I, II, or III meningioma. The maximum allowable dose will be calculated using dosimetry data acquired from PET/CT scans completed during a pre-treatment diagnostic & dosimetry phase using Cu-64 SARTATE, a structurally identical molecule radiolabelled with copper-64 (Cu-64), instead of copper-67 (Cu-67). Approximately 6 participants will be enrolled in the study. Participants will have up to 4 therapy cycles (6-12 weeks apart). Safety visits will occur between each cycle at bi-weekly intervals to ensure the participant meets the safety criteria prior to their next therapy. An efficacy assessment will be conducted following cycle 2 to determine if a subsequent 2 cycles of therapy will be administered. Participants who complete all four cycles of Cu-67 SARTATE therapy, will complete their final study visit at 12 weeks post administration of cycle 4.

Conditions

Meningioma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SARTATE

All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.

Group Type: EXPERIMENTAL

Cu-64 SARTATE and Cu-67 SARTATE

Intervention Type: DRUG

Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug

Interventions

Cu-64 SARTATE and Cu-67 SARTATE

Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug

Intervention Type: DRUG

Other Intervention Names

SARTATE; copper SARTATE; Cu-SARTATE; 64Cu-SARTATE; 67Cu-SARTATE; Cu-64 SARTATE; Cu-67 SARTATE; 64/67Cu-SARTATE; Cu-64/67 SARTATE

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent.

2. Age greater than or equal to 50 years.

3. Life expectancy greater than or equal to 3 months.

4. Has adequate organ function as defined by the following laboratory values obtained within 28 days prior to administration of Cu-64 SARTATE:

1. Estimated glomerular filtration rate (eGFR) greater than 40ml/min as measured using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3.0 x upper limit of normal (ULN).

3. QT interval less than /=450msec as measured by 12 lead ECG.

5. Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.

6. Diagnosis of recurrent or progressive histologically confirmed WHO grade I-III meningioma which has failed standard of care therapies. Patients will be considered to have failed standard care when they have disease that is progressing despite standard treatment (primarily radiotherapy) or where, in the opinion of their treating physician, further standard therapy is considered to be of sufficiently high risk of complication as to warrant consideration of alternate therapies.

7. Male participants must agree to use contraception methods from Day 0 through to 4 weeks after the last dose of Cu-67 SARTATE.

8. A female participant is eligible to participate if she is of:

1. Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and oestradiol less than 40 pg/ml (less than 140 pmol/l) is confirmatory].

2. Child-bearing potential and agrees to use contraception methods for an appropriate period of time (as determined by the Investigator) prior to Day 0 to sufficiently minimize the risk of pregnant females being enrolled. These measures are the combination of a barrier method AND established (greater than 2 cycles) hormonal methods (e.g. the oral contraceptive pill). Absolute sexual abstinence may be considered acceptable at the discretion of the investigator. Abstinence for the 12 days prior to therapy to allow for serum B-hCG assessment which should then ensure the patient is not pregnant prior to therapy administration.

3. Female participants must agree to use contraception until four weeks after the last dose of Cu-67 SARTATE.

Exclusion Criteria

1. Known sensitivity or allergy to somatostatin analogues.

2. Participants who have received interventional treatment for their meningioma within the four weeks prior to Day 0.

3. Any major surgery within the four weeks prior to Day 0.

4. Any additional planned interventions, including surgery or radiation therapy that would interfere with safety or efficacy assessments.

5. Treatment with long acting somatostatin analogues within 28 days prior to Day 0. Treatment with short acting somatostatin analogues within 24 hours prior to Day 0.

6. Any other malignancy in the past 5 years except for cervical intraepithelial neoplasia (CIN) of the cervix, squamous cell carcinoma (SCC) of the skin, basal cell carcinoma (BCC) of the skin or clinical insignificant prostate cancer not requiring prior therapy.

7. Breastfeeding females and pregnant females.

8. Treatment with any investigational agent received within four weeks prior to Day 0.

9. Participants unwilling or unable to comply with protocol requirements.

10. Urinary or faecal incontinence of sufficient degree to be of concern for contamination risk in the opinion of the Investigator.

11. Peptide receptor radionuclide therapy (PRRT) at any time prior to enrolment in the study.

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Clarity Pharmaceuticals Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Geoffrey Schembri, MD

Role: PRINCIPAL_INVESTIGATOR

Royal North Shore Hospital

Locations

Royal North Shore Hospital

Sydney, New South Wales, Australia

Countries

Australia

References

Bailey DL, Willowson KP, Harris M, Biggin C, Aslani A, Lengkeek NA, Stoner J, Eslick ME, Marquis H, Parker M, Roach PJ, Schembri GP. 64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry. J Nucl Med. 2023 May;64(5):704-710. doi: 10.2967/jnumed.122.264586. Epub 2022 Dec 2.

Reference Type: DERIVED

PMID: 36460344 (View on PubMed)

Other Identifiers

CL02

Identifier Type: -

Identifier Source: org_study_id